114 related articles for article (PubMed ID: 17515124)
1. [Continuous infusion of coagulant factor concentrates and its pharmacokinetics in patients with hemophilics having low titer inhibitor].
Fujii T; Takata N; Kimura A
Rinsho Ketsueki; 2007 Apr; 48(4):321-5. PubMed ID: 17515124
[TBL] [Abstract][Full Text] [Related]
2. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
[TBL] [Abstract][Full Text] [Related]
3. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates.
von Auer Ch; Oldenburg J; von Depka M; Escuriola-Ettinghausen C; Kurnik K; Lenk H; Scharrer I
Ann N Y Acad Sci; 2005 Jun; 1051():498-505. PubMed ID: 16126990
[TBL] [Abstract][Full Text] [Related]
4. Early experience with the use of anti-inhibitor coagulant complex to treat bleeding in hemophiliacs with inhibitors to factor VIII.
Kantrowitz JL; Lee ML; McClure DA; Kingdon HS; Thomas WR
Clin Ther; 1987; 9(4):405-19. PubMed ID: 3111706
[TBL] [Abstract][Full Text] [Related]
5. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
6. Elective cardiac operation in a patient with severe hemophilia and acquired factor VIII antibodies.
Leggett PL; Doyle D; Smith WB; Culpepper W; Cooper S; Ochsner JL
J Thorac Cardiovasc Surg; 1984 Apr; 87(4):556-60. PubMed ID: 6423912
[TBL] [Abstract][Full Text] [Related]
7. Hemostasis: a practical review of conservative and operative care.
Shopnick RI; Brettler DB
Clin Orthop Relat Res; 1996 Jul; (328):34-8. PubMed ID: 8653974
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
[TBL] [Abstract][Full Text] [Related]
9. Extracorporeal immunoadsorption for the treatment of coagulation inhibitors.
Franchini M; Sassi M; Dell'Anna P; Manzato F; Salvagno GL; Montagnana M; Zaffanello M; Targher G; Lippi G
Semin Thromb Hemost; 2009 Feb; 35(1):76-80. PubMed ID: 19308895
[TBL] [Abstract][Full Text] [Related]
10. Needles and needleless devices for infusion of anti-haemophilic factor concentrate: impact on protein structure and function.
Prabhu S; Kazarian T; Hakobyan N; Jabbar A; Dunham T; Valentino LA
Haemophilia; 2006 Jan; 12(1):58-61. PubMed ID: 16409176
[TBL] [Abstract][Full Text] [Related]
11. Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B.
Martinowitz UP; Schulman S
Acta Haematol; 1995; 94 Suppl 1():35-42. PubMed ID: 7571993
[TBL] [Abstract][Full Text] [Related]
12. Trends in the utilization and wastage of coagulation factor concentrates: the application of a regional tracking programme.
Arnold DM; Webert KE; Carruthers J; Almonte T; Decker K; Seroski W; Reed J; Chan AK; Pai M; Walker I
Haemophilia; 2007 May; 13(3):271-8. PubMed ID: 17498076
[TBL] [Abstract][Full Text] [Related]
13. Novel drugs to treat hemophilia.
Valentino LA; Ismael Y; Grygotis M
Expert Opin Emerg Drugs; 2010 Dec; 15(4):597-613. PubMed ID: 20653467
[TBL] [Abstract][Full Text] [Related]
14. Recombinant infusion therapies indicated for bleeding disorders.
Kauffman J
J Infus Nurs; 2011; 34(1):29-35. PubMed ID: 21239949
[TBL] [Abstract][Full Text] [Related]
15. [News in the treatment of patients with hemophilia. Virus-inactivated coagulation factor concentrates, artificial joints and prenatal diagnosis].
Stavem P; Evensen SA; Solheim B; Teigland JC
Tidsskr Nor Laegeforen; 1989 May; 109(14):1539-42. PubMed ID: 2749644
[TBL] [Abstract][Full Text] [Related]
16. Safety of human plasma-derived clotting factor products and their role in haemostasis in patients with haemophilia: meeting report.
Tarantino M; Ma A; Aledort L
Haemophilia; 2007 Sep; 13(5):663-9. PubMed ID: 17880460
[No Abstract] [Full Text] [Related]
17. Comprehensive hemophilia care and home factor infusions.
Brettler DB
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():41-2. PubMed ID: 7886603
[No Abstract] [Full Text] [Related]
18. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
Gringeri A; Musso R; Mazzucconi MG; Piseddu G; Schiavoni M; Pignoloni P; Mannucci PM;
Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
[TBL] [Abstract][Full Text] [Related]
19. Plasma-derived biological medicines used to promote haemostasis.
Ofosu FA; Freedman J; Semple JW
Thromb Haemost; 2008 May; 99(5):851-62. PubMed ID: 18449414
[TBL] [Abstract][Full Text] [Related]
20. Enhanced communication between care professionals and patients with hemophilia by using a web enabled electronic logbook.
Roosendaal G; Drenth ER; Poerschke M; Verkerk EC; Van den Berg HM; Metselaar M
Stud Health Technol Inform; 2004; 103():191-4. PubMed ID: 15747920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
